Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.
Introduction
Surgical resection is the treatment of choice for patients with localized non-small cell lung cancer (NSCLC). Unfortunately, at the time of diagnosis, fewer than 25% of all NSCLC patients are considered candidates for surgical therapy, and cure after resection is highly dependent on the stage of disease and lymph nodes involvement. Patients without lymph node metastases, who have been completely resected, have a 5-year survival rate of more than 70%. This rate decreases to 50% and 15%, respectively, if hilar or mediastinal nodes are involved [1] .
Analyses of sites of recurrence revealed that two-thirds of all recurrences following a complete resection occurred distantly. In a fair number of occasions, the brain was the first metastatic site to be recognized [2] . The urgent need for better treatment of a disease with such a systemic nature has led to several studies employing chemotherapy in addition to local (surgical) treatment as adjuvant [3] or neoadjuvant role.
Stage IIIA-N2 NSCLC, is a heterogeneous disease. According to Ruckdeschel [4] , hipsi lateral mediastinal spread can be roughly divided into three groups: patients with minimal N2 involvement, found incidentally at during or after surgery; patients with N2 disease diagnosed preoperatively, with imaging or surgical procedures; patients with multi-station bulky-N2 involvement. While there is consensus to treat patients with bulky-N2 in the same group as locally advanced IIIB disease, and to treat with primary surgical resection patients with incidental or minimal N2 involvement [5] , still there is no agreement about the best approach to patients with hipsilateral mediastinal lymph node metastasis diagnosed preoperatively, though considered technically potentially resectable.
In fact, as assessed in a large retrospective study by Andre et al. [6] , among patients with resected stage IIIA-N2 NSCLC, a significant difference in prognosis was reported not only between clinical N2 and minimal N2 involvement, but also between single-station metastasis and multi-station metastasis.
Giving the bad prognosis that NSCLC acquires when it spreads to the mediastinum, the use of systemic therapy before definitive local therapy, generally referred to as induction or neoadjuvant therapy aims to: prevent the growth of systemic disease and, at the same time, shrink the loco-regional macroscopic disease, which may then be adequately treated by surgery; early eradicate micro-metastases; prolong overall survival.
These advantages must be weighed against concerns regarding increased morbidity and mortality of a combined modality approach and, in case of an ineffective induction regimen, progression of local disease in patients whose tumour could have been resected initially.
There have been several phase II feasibility trials of induction chemotherapy followed by surgical resection [7 -9] .
Despite the significant variability of these studies, however, a number of general conclusions can be made. The response rates resulting from chemotherapy in patients with good performance status and stage III and early-stage disease are significantly higher than those seen in patients with stage IV disease; complete pathologic responses occurred in 5-15% of patients and median survival ranged from 9-30 months, with an average median of approximately 17 months. Furthermore, it became apparent that downstaging of mediastinal lymph nodes and complete surgical resection are reliable predictors of long-term survival [10] . On the other hand, it was also noted that survival of patients with persistent N2 disease or incompletely resected tumours remains disappointing.
Randomised trials of induction chemotherapy
A small number of phase III trials that compared induction chemotherapy to surgery alone have been reported. Three of these studies, albeit with a small number of patients, and using different induction regimens, showed similar outcomes, with superior survival rates in the treatment arm that included chemotherapy [11] [12] [13] (Table 1 ). In two of these studies, the survival differences were so impressive that they were stopped prematurely [11, 12] . The median survival time was 21 versus 14 months in the combination arm and surgery alone arm, respectively, in the MD Anderson study, and 22 versus 10 months in the Spanish study. It appeared then, that induction therapy of short duration is able to alter the natural development of NSCLC that has spread to the mediastinum. Moreover, as shown in updated reports of these trials, the survival advantage gained with neoadjuvant chemotherapy was long-lasting [14, 15] . It is noteworthy the attitude towards post-operative treatment. In the Spanish trial, all patients received adjuvant thoracic radiotherapy, while in the USA trial, thoracic radiotherapy was administered only in patients with incompletely resected or unresectable disease. Moreover, in this latter study, patients responding to induction therapy received further 3 cycle of the same regimen as adjuvant chemotherapy.
The largest of these phase III trials is a French study that randomised patients with resectable (IB-IIIA) NSCLC to two cycles of MIP (mitomycin, ifosfamide, cisplatin) induction chemotherapy (and two more cycles after surgery) or surgery alone [13] . Though median survival time was 37 months in the combination treatment arm, and 26 months in the surgery alone arm, this striking difference was not significant (logrank P = 0.15). Interestingly, at the multivariate analysis, a favourable effect of the combined modality approach was noted among patients presenting with the earliest stages of disease (N0-N1). In the same study, there was a suggestion of increased morbidity in the combined study arm. The specific composition of the induction regimen (mitomycin) might have been responsible for this observation, though, in general, induction therapy does not seem to significantly increase the morbidity of chest surgery.
These results have not been confirmed by a Japanese phase III trial [16] . Though this study was addressed only to histologically confirmed N2 patients, did not allow adjuvant treatment, and scheduled post-operative radiotherapy only for incompletely resected patients, induction chemotherapy did not increase survival compared to surgery alone (median survival time of 17 versus 16 months respectively) and the trial was prematurely stopped, but for too slow accrual.
In summary, though pioneer, the major limitations of these studies were: (a) a small sample size; (b) an often lack of rigorous pre-treatment surgical assessment of mediastinal spread; 
New induction regimens: platinum-based doublets
Newer chemotherapeutic agents, such as gemcitabine and the taxanes, have shown activity in patients with advanced NSCLC. Because platinum is still being regarded as the backbone of chemotherapy for NSCLC, new platinum-based combinations were the first to be tested as induction regimens [17] . Three platinum-based chemotherapy combinations have been recently tested ( Table 2 ). The European Organisation for the Research and Treatment of Cancer (EORTC) Lung Cancer Group was the first to study gemcitabine/cisplatin (GC) as an induction regimen. Early suggestions of increased efficacy of this combination in patients with advanced disease [18] prompted the EORTC to initiate a phase II trial in patients with stage IIIA, biopsy-proven, N2 disease [19] . Forty-seven patients were registered to receive three cycles of the GC combination, administered with a 4-week schedule. This chemotherapy regimen was tolerated rather well and produced a high response rate. Independent evaluation of CT scans of all responding patients, excluding those patients who received less than three prescribed GC courses (intent-to-treat analysis), revealed a 70.2% objective response rate. Ninety-four percent of the patients who underwent surgery were deemed resectable, of whom 71% had complete resection. Mediastinal nodes were rendered free of tumour in 53% of cases. Overall median survival was 18.9 months and 1-year survival was 69% (95% CI, 56% to 82%).
The Lung Cancer Project Group of the Swiss Group for Clinical Cancer Research (SAKK) has performed a similar trial designed to analyse the docetaxel/cisplatin (DC) combination as an induction regimen in patients with respectable stage IIIA disease. A radiographic response was shown in 66% of patients, with negative first mediastinal lymph node upon surgery occurring in 60% [20] .
The activity of the paclitaxel-carboplatin combination on N2 disease has been assessed by O'Brien et al. [21] . The response rate was 66%. As in the Van Zandwjik et al. trial [19] , even this study has been part of a wider phase III trial, where patients responding to induction chemotherapy were randomly assigned to receive either surgery or radiotherapy (EORTC 08 941). Though this study tends to assess the best treatment for stage IIIA-N2 disease, the complete pathological staging after induction treatment is being performed only in patients randomised to the surgery arm, and this could insert some limitations in evaluating the survival results according to the madiastinal lymph-node status.
Finally, the GC combination, administered with a 3-week schedule, has been tested as induction treatment in other 3 phase II trials [22] [23] [24] . It is noteworthy the different target population enrolled in these studies, that goes from selected N2 and IIIB (non-N3) patients [23] to locally advanced, unresectable disease [24] . In this heterogeneous population, the GC combination seemed to be extremely active, with response rates ranging from 57% to 67%, and with a rate of surgical resectability following induction treatment that ranged from 30% to 40% of cases. Treatment was generally well tolerated, with myelosuppression being, as expected, the main toxicity. Grade 3-4 neutropenia was recorded in 27% and 37% of patients in the Santo et al. [22] and Cappuzzo et al. [24] trials, respectively, while the main toxicity in the Migliorino et al. [23] trial was grade 3 -4 thrombocytopenia (26% of patients).
All studies with the newer combinations reported few postoperative complications. A comparison of the old (three-drug) regimens, such as MVP (mitomycin, vinblastine, and cisplatin) and MIC (mitomycin, ifosfamide, and cisplatin), and the new doublets suggests that the new doublets have a milder toxicity profile. Another important finding, especially in the EORTC and SAKK studies, was the low percentage of patients who progressed during induction therapy, which encourages the use of these combinations in patients with early-stage disease. 
New induction regimens: platinum-based triplets
Recent data indicate high activity of three-drug chemotherapy regimens in advanced NSCLC in terms of response rate [25] . Although a meta-analysis failed to demonstrate any benefit in terms of overall survival in metastatic disease [26] , activity of these combinations needs to be tested in earlier stages NSCLC. Thus, in order to improve activity of induction chemotherapy in stage III NSCLC patients, in terms of response rate as well as in terms of surgical resectability, two 3-drugs combinations have been studied in phase II trials ( Table 3 ). The activity of the triplet cisplatin, gemcitabine, paclitaxel (CGP) has been assessed in two similar Italian trials. The main difference between these two studies was the patients population, being confined to N2 disease in one study [27] and extended to selected stage IIIB disease in the other study [28] . In both trials, pre-treatment surgical evaluation of mediastinal lymph-node status was mandatory. Overall, response rate and median survival time were approximately 70% and 20 months, respectively. The toxicity of this schedule was mild and mainly haematological (grade 3-4 neutropenia reported in almost 30% of patients in both studies).
On the other hand, a Spanish trial [29] assessed the activity of the triplet cisplatin, vinorelbine, gemcitabine, as induction treatment in locally advanced disease. This regimen reached a response rate of 52%, and a median survival time of 10 months. Compared to the CGP combination, these results seem disappointing. Though, the patient population selected in the Spanish trial was at worse prognosis compared to the Italian trials (76% of patients with stage IIIB versus 38% and 0% in the Cappuzzo et al. [28] and De Marinis et al. [27] trials, respectively). This could have lead to a lower probability of down-staging after induction chemotherapy, a less possibility of performing radical surgery, and thus to a shorter overall survival.
Role of radiotherapy as induction treatment
Radiotherapy plays a leading role in the treatment of locally advanced NSCLC, often in combination with chemotherapy. Though, its role in the management of resectable N2 disease is still controversial. A phase III study (the Intergroup 0139 trial) [30] , randomises patients who respond to concurrent induction chemo-radiotherapy (CRT), to receive surgery or consolidation radiotherapy, followed in both arms by two further cycle of adjuvant chemotherapy. This trial will assess not only the role of CRT as neoadjuvant treatment in N2 disease, but even the role of surgical resection following a combination treatment that itself aims to be curative.
From N2 to early stage disease: ongoing studies in resectable NSCLC
Recent evidence from phase III trials has shown that adjuvant chemotherapy with third generation platinum-based doublets can be safely be administered in early stage disease, and that it improves survival. In fact, two randomised studies have assessed the impact of post-surgical chemotherapy in patients without mediastinal involvement. In the CALGB trial [31] the chemotherapy arm consisted of carboplatin/paclitaxel, and the target population was stage IB disease: 4-year survival was 71% versus 59% in the chemotherapy and non-chemotherapy arm respectively. In the JBR.10 study [32] , chemotherapy consisted of cisplatin/vinorelbine, and target population was resected patients with stage IB-II disease: 5-year survival was 69% versus 54% in the chemotherapy and non-chemotherapy arm respectively.
These data, together with the positive results of the Depierre et al study [13] , on neoadjuvant treatment for patients with stage IB-II disease, have confirmed the role of chemotherapy even in early-stage NSCLC.
Moreover, feasibility and tolerability of neoadjuvant treatment for early stage disease was further assessed in a multicenter United States phase II study. Ninety-four patients with T2N0, T1-2N1, and T3N0-1 NSCLC and negative mediastinoscopy received two cycles of induction paclitaxel/carboplatin followed by surgery and then three additional cycles of the same chemotherapy combination (BLOT) [33] . After induction therapy, 53 (56%) of 94 patients had an objective response, 88 (94%) underwent surgical exploration, and 81 (86%) underwent complete resection.
Nevertheless, neoadjuvant treatment seems to be more tolerated than adjuvant chemotherapy (96% versus 65% of patients completing all planned cycles of chemotherapy in the BLOT and JBR.10 studies respectively).
For these reasons, several randomised phase III trials have been started to compare induction treatment followed by surgery versus surgery alone in early stage NSCLC. These trials are listed in Table 4 . It is noteworthy that most of these studies suffered from too slow accrual, partly because of the gaining interest toward adjuvant treatment, and to drive definite conclusions and maintain statistical power, some of them had to be combined together. Hopefully, the question about adjuvant versus neo-adjuvant treatment will be solved by the NACTH study that randomises patients to both treatments or to surgery alone.
Tailoring treatment through molecular markers analysis
The analysis of molecular markers involved in the development of lung cancer, as well as in its constitutive or acquired resistance to treatment, is a novel ad interesting field of research. Neoadjuvant treatment is a particularly favourable setting for this kind of analysis, because the response rate is higher, compared to advanced disease, and thus it is easier to select comparable groups of patients according to treatment response, and samples can be collected before and after chemotherapy, and thus compared. This latter question has been addressed by an interesting report by Meert et al. [34] , who demonstrated the feasibility of immunohistochemical assessment of common NSCLC markers (p53, Ki-67, c-erb-B2 and EGFR) on presurgical biopsy, and the comparable results obtained by the same assessment performed on the final surgical specimen.
Several markers have been investigated as predictive of response to induction chemotherapy, especially p53 protein over-expression and gene mutations. Unfortunately, most of these studies are retrospective, performed on small samples, and showing conflicting results (Table 5) . Thus, no definite conclusions can be drawn yet. Nevertheless, of particular interest are the studies by Kandioler-Eckersberger et al. [35] and by Rosell et al. [36] . In the first study, though in a small cohort of patients, p53 seemed to be a predictor of worse response to chemotherapy only by the assessment of its gene mutations, but not by the protein over-expression. In the latter, and larger, study mRNA expression of ribonucleotide reductase subunit M1 (RRM1) showed to be a useful predictor of worse response to cisplatin/gemcitabine combination. As in advanced disease, it seems that the expressions of this kind of enzymes, involved in DNA repair, are the most reliable molecules involved in cisplatin sensitivity.
Conclusions
Apart from a minority of patients with very early-stage disease, most NSCLC patients who are candidates for surgical [37] . Its further role in early-stage disease will be assessed by ongoing phase III trials. Finally, proper treatment tailoring through molecular markers analysis will lead to the optimal management of these patients.
